Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cell Source's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-16.03 Mil. Cell Source's Total Assets for the quarter that ended in Sep. 2023 was $0.25 Mil.
The historical rank and industry rank for Cell Source's Equity-to-Asset or its related term are showing as below:
CLCS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -239.27 Med: -31.05 Max: -0.5
Current: -64.64
During the past 11 years, the highest Equity to Asset Ratio of Cell Source was -0.50. The lowest was -239.27. And the median was -31.05.
CLCS's Equity-to-Asset is ranked worse than 99.36% of 1565
companies
in the Biotechnology industry
Industry Median: 0.67
vs CLCS: -64.64
Cell Source Equity-to-Asset Historical Data
The historical data trend for Cell Source's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cell Source's Equity-to-Asset
For the Biotechnology subindustry, Cell Source's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Source's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cell Source's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cell Source's Equity-to-Asset falls into.
Cell Source Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cell Source's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cell Source Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Cell Source's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLCS has been successfully added to your 